Clinical Trial: Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07908446) titled 'Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV' on Oct. 26.

Brief Summary: The goal of this clinical trial is to assess the effectiveness and safety of switching to bictegravir/lenacapavir (BIC/LEN) fixed-dose combination (FDC) compared with continuing stable baseline regimens (SBR) in virologically suppressed people with HIV.

The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) fixed-dose combination (FDC) tablets versus continuing their stable baseline regimen (SBR) in virologically suppressed people with HIV.

Study Start Date: Nov., 2...